US 12,227,494 B2
Polymorphisms of HM30181 mesylate
Sameer Urgaonkar, Williamsville, NY (US); Michael P. Smolinski, Amherst, NY (US); and Johnson Yiu-Nam Lau, Houston, TX (US)
Assigned to HEALTH HOPE PHARMA LIMITED, Hong Kong (CN)
Filed by ATHENEX R&D, LLC, Buffalo, NY (US)
Filed on Apr. 19, 2023, as Appl. No. 18/136,765.
Application 18/136,765 is a division of application No. 17/513,448, filed on Oct. 28, 2021, granted, now 11,739,079.
Claims priority of provisional application 63/107,720, filed on Oct. 30, 2020.
Claims priority of provisional application 63/107,792, filed on Oct. 30, 2020.
Prior Publication US 2024/0116904 A1, Apr. 11, 2024
Int. Cl. C07D 405/14 (2006.01); A61K 45/06 (2006.01)
CPC C07D 405/14 (2013.01) [A61K 45/06 (2013.01); C07B 2200/13 (2013.01)] 3 Claims
OG exemplary drawing
 
1. A composition comprising a crystalline form of HM30181 mesylate, where the crystalline form is polymorph B, and wherein the crystalline form has an X-ray diffraction pattern corresponding to FIG. 40 and has an endotherm at about 159.92° C.